Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 7:2020:8345235.
doi: 10.1155/2020/8345235. eCollection 2020.

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer

Huanhuan Yin  1 , Wei Guo  1 , Xiangling Sun  1 , Ruili Li  1 , Cuihua Feng  1 , Yujie Tan  1
Affiliations

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer

Huanhuan Yin et al. J Immunol Res. .

Abstract

Background: We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative.

Methods: A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients.

Results: The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy.

Conclusion: Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for PFS and OS of metastatic cervical cancer. (a) Patients' PFS curve. (b) Patients' OS curve.
Figure 2
Figure 2
Patients exhibiting a CR of multiple lung metastases and liver metastases after TILs plus anti-PD1 therapy. (a) The patient achieved a CR of multiple lung metastases (the yellow arrows) after 3 months of immunotherapy. (b) The patient achieved a CR of multiple liver metastases (the yellow arrows) after 4 months of immunotherapy.
Figure 3
Figure 3
Kaplan–Meier curves for PFS and OS of patients with ORR (CR+PR), N = 20 and non-ORR, N = 60. (a) The PFS curve of patients with ORR and non-ORR. (b) The OS curve of patients with ORR and non-ORR.
Figure 4
Figure 4
Univariate analyses of more infusion (TIL numbers and CD8+TIL percentage), less infusion (CD8+PD1+ TIL percentage and CD4+FoxP3+TIL percentage), and HPV status and having fever or not after immunotherapy based on PFS. PFS curve for: (a) patients with more TIL numbers (≥50 × 109, red line) and less TIL numbers (<50 × 109, blue line); (b) patients with more CD8+ TIL (≥60%, red line) and less CD8+ TIL (<60%, blue line); (c) patients with more CD8+PD1+ TIL (≥10%, red line) and less CD8+PD1+ TIL (<10%, blue line); (d) patients with more CD4+FoxP3+ TIL (≥20%, red line) and less CD4+FoxP3+ TIL (<20%, blue line); (e) patients with HPV+ (red line) and HPV− (blue line); and (f) patients having fever (red line) and no fever (blue line) after immunotherapy.
Figure 5
Figure 5
Univariate analyses of more infusion (TIL numbers and CD8+ TIL percentage), less infusion (CD8+PD1+ TIL percentage and CD4+FoxP3+ TIL percentage), and HPV status and having fever or not after immunotherapy based on OS. OS curve for: (a) patients with more TIL numbers (≥50 × 109, red line) and less TIL numbers (<50 × 109, blue line); (b) patients with more CD8+ TIL (≥60%, red line) and less CD8+ TIL (<60%, blue line); (c) patients with more CD8+PD1+ TIL (≥10%, red line) and less CD8+PD1+ TIL (<10%, blue line); (d) patients with more CD4+FoxP3+ TIL (≥20%, red line) and less CD4+FoxP3+ TIL (<20%, blue line); (e) patients with HPV+ (red line) and HPV− (blue line); and (f) patients having fever (red line) and no fever (blue line) after immunotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kamangar F., Dores G. M., Anderson W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology. 2006;24(14):2137–2150. doi: 10.1200/JCO.2005.05.2308. - DOI - PubMed
    1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: a Cancer Journal for Clinicians. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2020. CA: a Cancer Journal for Clinicians. 2020;70(1):7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Sherman M. E., Wang S. S., Carreon J., Devesa S. S. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer. 2005;103(6):1258–1264. doi: 10.1002/cncr.20877. - DOI - PubMed
    1. Howe H. L., Wu X., Ries L. A. G., et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711–1742. doi: 10.1002/cncr.22193. - DOI - PubMed

MeSH terms